^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Regimen:TPF (5-fluorouracil + cisplatin + docetaxel)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    10/11/2019
    Excerpt:
    Docetaxel Injection is a microtubule inhibitor indicated for:...Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Docetaxel Teva in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/09/2021
    Excerpt:
    Esophageal and esophageal junction cancer Gastric cancer: Other recommended regimens- continued...Docetaxel, cisplatin or oxaliplatin, and fluorouracil